Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

about

Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.A case of "pseudo-ketoacidosis".

P2860

Q38250445-60ABCD35-FC5A-48C0-B505-FCF196A4C5A4 Q41846233-4A65E264-53C6-425C-821F-43F3CE10F6F4

P2860

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

Item

http://www.wikidata.org/entity/Q38196340

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

@en

type

Item

label

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

@en

prefLabel

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

@en

P1476

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

@en

P2093

Manoj Kumar

http://www.w3.org/2001/XMLSchema#string

Priyanka Malla

http://www.w3.org/2001/XMLSchema#string

Rajnish Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and classification of diabetes mellitus

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.

SGLT2 inhibition--a novel strategy for diabetes treatment.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

P304

1146-1167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MED.21314

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manoj Kumar Mahapatra

P577

2014-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260803370

http://www.w3.org/2001/XMLSchema#string

P698

24633706

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

about

P2860

P2860

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921